UCB/€UCB
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About UCB
UCB SA, founded in 1928, is a global biopharmaceutical company headquartered in Brussels, Belgium. The company specializes in the research, development, and commercialization of innovative therapies primarily for the treatment of neurological and immunological disorders. Operating in the healthcare sector, UCB is dedicated to advancing science and addressing unmet medical needs for patients worldwide.
- Ticker
- €UCB
- Sector
- Health
- Primary listing
- BSE
- Employees
- 9,000
- Headquarters
- Brussels, Belgium
- Website
- www.ucb.com
UCB Metrics
BasicAdvanced
€54B
24.64
€11.32
0.19
€1.02
0.36%
Price and volume
Market cap
€54B
Beta
0.19
52-week high
€288.90
52-week low
€200.30
Average daily volume
304K
Dividend rate
€1.02
Financial strength
Current ratio
1.203
Quick ratio
0.724
Long term debt to equity
0.289
Total debt to equity
0.308
Dividend payout ratio (TTM)
12.58%
Interest coverage (TTM)
29.90%
Profitability
EBITDA (TTM)
3,138
Gross margin (TTM)
76.22%
Net profit margin (TTM)
25.74%
Operating margin (TTM)
29.47%
Effective tax rate (TTM)
13.38%
Revenue per employee (TTM)
€950,000
Management effectiveness
Return on assets (TTM)
8.30%
Return on equity (TTM)
20.57%
Valuation
Price to earnings (TTM)
24.64
Price to revenue (TTM)
6.231
Price to book
4.6
Price to tangible book (TTM)
118.96
Price to free cash flow (TTM)
41.336
Free cash flow yield (TTM)
2.42%
Free cash flow per share (TTM)
6.748
Dividend yield (TTM)
0.36%
Forward dividend yield
0.36%
Growth
Revenue change (TTM)
24.47%
Earnings per share change (TTM)
64.86%
3-year revenue growth (CAGR)
18.59%
10-year revenue growth (CAGR)
7.98%
3-year earnings per share growth (CAGR)
88.56%
10-year earnings per share growth (CAGR)
12.62%
3-year dividend per share growth (CAGR)
2.92%
10-year dividend per share growth (CAGR)
2.80%
What the Analysts think about UCB
Analyst ratings (Buy, Hold, Sell) for UCB stock.
Analyst projections of the future price of UCB stock.
Bulls say / Bears say
UCB raised its 2026 outlook again, now expecting revenue growth in the low twenties and adjusted EBITDA growth in the low-to-mid forties at constant exchange rates. That points to strong demand and substantial operating leverage. (UCB)
BIMZELX sales rose 91% in the first half to €1.53 billion, and UCB lifted its peak-sales ambition to at least €7 billion. Head-to-head superiority data in psoriatic arthritis strengthens its case against rivals. (UCB)
Growth is spreading across newer medicines: first-half sales rose 32% for RYSTIGGO, 49% for ZILBRYSQ, 18% for FINTEPLA and 39% for EVENITY. This gives UCB growth drivers beyond BIMZELX. (UCB)
Generic competition is eroding older products: BRIVIACT sales fell 13% in the first half after losing US exclusivity, while VIMPAT sales were hit by generic entry in Japan. These declines will need to be offset by newer medicines. (UCB)
Some first-half results benefited from favourable adjustments relating to prior-year estimates, while UCB flagged further net-price pressure from expanded BIMZELX access. This makes it harder to assume the first-half growth rate will persist unchanged. (UCB)
Data summarised monthly by Lightyear AI. Last updated on 22 Oct 2026.
UCB Financial Performance
Revenues and expenses
UCB Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing UCB
AllEURUSDGBP
Fund name | Fund size | €UCB weighting |
|---|---|---|
iShares MSCI Europe Health Care Sector£ESIH | €890M | 1.96% |
iShares MSCI Europe Health Care Sector€ESIH | €890M | 1.96% |
iShares STOXX Europe 600 Health Care€EXV4 | €709M | 1.90% |
iShares Healthcare Innovation£DRDR | $1.3B | 1.21% |
iShares Healthcare Innovation€2B78 | $1.2B | 1.21% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.